Cathepsin expression in oral squamous cell carcinoma: Relationship with clinicopathologic factors

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 93, Issue 4, 2002, Pages 446-454

  Kawasaki, Goro ^a,c   Kato, Yuzo ^b   Mizuno, Akio ^a  

^a Division of Oral and Maxillofacial Surgery   (Japan)

^b Department of Pharmacology ^*  (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; CATHEPSIN B; CATHEPSIN D; CATHEPSIN H; CATHEPSIN L; CYCLINE; CYSTEINE PROTEINASE; ENZYME PRECURSOR; TUMOR MARKER;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CANCER INVASION; CANCER STAGING; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GINGIVA TUMOR; HUMAN; MALE; METASTASIS; MIDDLE AGED; MOUTH; MOUTH TUMOR; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; STATISTICAL MODEL; STATISTICS; SURVIVAL RATE; TONGUE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, SQUAMOUS CELL; CATHEPSIN B; CATHEPSIN D; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; ENZYME PRECURSORS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GINGIVAL NEOPLASMS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MOUTH FLOOR; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; STATISTICS; SURVIVAL RATE; TONGUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036527896     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1067/moe.2002.122834     Document Type: Article

References (33)

1. Saku T, Sakai H, Tsuda N, Okabe H, Kato Y, Yamamoto K. Cathepsin D and E in normal, metaplastic, dysplastic, and carcinomatous gastric tissue: an immunohistochemical study. Gut 1990;31:1250-5.
2. Lipponen PK. Expression of cathepsin D in transitional cell bladder tumours. J Pathol 1996;178:59-64.
3. Tumminello FM, Leto G, Pizzolanti G, Candiloro V, Crescimanno M, Crosta L, et al. Cathepsin D, B and L circulating levels as prognostic markers of malignant progression. Anticancer Res 1996;16:2315-20.
4. Ledakis P, Tester WT, Rosenberg N, Fischmann D, Daskal I, Lah TT. Cathepsin D, B, and L in malignant human lung tissue. Clin Cancer Res 1996;2:561-8.
5. Fujise N, Nanashima A, Taniguchi Y, Matsuo S, Hatano K, Matsumoto Y, et al. Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinoma by immunohistochemical study. Lung Cancer 2000;27:19-26.
6. Kandalaft P, Chang KL, Ahn CW, Traweek ST, Mehta P, Battifora H. Prognostic significance of immunohistochemical analysis of cathepsin D in low-stage breast cancer. Cancer 1993;71:2756-63.
7. Rochefort H, Garcia M, Glondu M, Laurent V, Liaudet E, Rey JM, et al. Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 2000;291:157-70.
8. Hirai K, Yokoyama M, Asano G, Tanaka S. Expression of cathepsin B and cystatin C in human colorectal cancer. Hum Pathol 1999;30:680-6.
9. Anneroth G, Batsakis J, Luna M. Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res 1987;95:229-49.
10. Yamamoto K, Ueno E, Uemura H, Kato Y. Biochemical and immunochemical similarity between erythrocyte membrane aspartic proteinase and cathepsin E. Biochem Biophys Res Commun 1987;148:267-72.
11. Kawasaki G, Mataki S, Mizuno A. Ultrastructural and biochemical studies of the effect of polychlorinated biphenyl on mouse parotid gland cells. Arch Oral Biol 1995;40:39-46.
12. Barret AJ, Kirschke H. Cathepsin B, cathepsin H, and cathepsin L. In: Dennis MG, Dennis EA, editors. Methods in Enzymology. New York: Academic Press; 1981 (Vol 80). p. 531-61.
13. Lowry OH, Rosebrough NJ, Far AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biochem 1951;193:265-75.
14. Koblinski JE, Abram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000; 291:113-35.
15. Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 2000;1477:98-111.
16. Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J. Cathepsin D in tissue and serum of patients with squamous cell carcinoma of the head and neck. Cancer Lett 1998;130:49-56.
17. Sanchez-Martin MM, Cabezas JA, Ortega S, Garcia J, Garcia-Criando FJG, Pina J, et al. Levels of serum cathepsin L and several glycosidases in patients operated for colorectal cancer. Cancer Lett 1999;141:73-7.
18. Thomas GT, Lewis MP, Speight PM. Matrix metalloproteinases and oral cancer. Oral Oncol 1999;35:227-33.
19. Hong SD, Hong SP, Lee JI, Lim CY. Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol 2000;36:207-13.
20. Koop S, Khokha R, Schmidt EE, MacDonald IC, Morris VL, Chambers AF, et al. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 1994;54:4791-7.
21. Visscher DW, Sloane BF, Sameni M, Babiarz JW, Jacobson J, Crissman JD, et al. Clinicopathologic significance of cathepsin B immunostaining in transitional neoplasia. Mod Pathol 1994;7:76-81.
22. Khan A, Krishna M, Baker SP, Malhothra R, Banner BF. Cathepsin B expression and its correlation with tumor-associated laminin and tumor progression in gastric cancer. Arch Pathol Lab Med 1998;122:172-7.
23. Sukoh N, Abe S, Ogura S, Isobe H, Takekawa H, Inoue K, et al. Immunohistochemical study of cathepsin B. Prognostic significance in human lung cancer. Cancer 1994;74:46-51.
24. Jessep JM. Cathepsin B and other proteases in human colorectal carcinoma. Am J Pathol 1994;145:253-62.
25. Kos J, Lah TT. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer. Oncol Rep 1998;5:1349-61.
26. Moin K, Day NA, Sameni M, Hasnain S, Hirama T, Sloane BF. Human tumour cathepsin B. Comparison with normal liver cathepsin B. Biochem J 1992;285:427-34.
27. Rescheleit DK, Rommerskirch WJ, Wiederanders B. Sequence analysis and distribution of two new human cathepsin L splice variants. FEBS Lett 1996;394:345-8.
28. Mehtani S, Gong Q, Panella J, Subbiah S, Peffley DM, Frankfater A. In vivo expression of an alternatively spliced human tumor message that encodes a truncated form of cathepsin B. Subcellular distribution of the truncated enzyme in COS cells. J Biol Chem 1998;273:13236-44.
29. Coopman PJ, Thomas DM, Gehlsen KR, Mueller SC. Integrin alpha 3 beta 1 participates in the phagocytosis of extracellular matrix molecules by human breast cancer cells. Mol Biol Cell 1996;7:1789-804.
30. Montcourrier P, Mangeat PH, Salazar G, Morisset M, Sahuquet A, Rochefort H. Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles. Cancer Res 1990;50:6045-54.
31. Montcourrier P, Mangeat PH, Valembois C, Salazar G, Sahuquet A, Duperray C, et al. Characterization of very acidic phagosomes in breast cancer cells and their association with invasion. Cell Sci 1994;107:2381-91.
32. Zeillinger R, Swoboda H, Machacek E, Nekahm D, Sliutz G, Knogler W, et al. Expression of cathepsin D in head and neck cancer. Eur J Cancer 1992;28A:1413-5.
33. Cavalilles V, Garcia M, Rochefort H. Regulation of cathepsin D and pS2 gene expression by growth factors in MCF7 human breast cancer cells. Mol Endocrinol 1989;3:552-8.